ArticleMolecular biology reports2025
Kaempferol suppresses TLR-2 and TLR-4 coactivation by attenuation of LPS/LTA-induced inflammation and cellular stress.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Kaempferol: advances in biosynthesis, molecular mechanisms, and therapeutic applications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Quercetin alleviates incontinence-associated dermatitis via IKK/NF-κB pathway.Scientific reports · 2026Article
- Reactive oxygen species in skin diseases: pathogenic mechanisms and nanomaterial-based therapeutic strategies.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBacterial pathogen-associated molecular patterns (PAMPs), specifically lipopolysaccharide (LPS) from Gram-negative bacteria (E. coli, P. aeruginosa) and lipoteichoic acid (LTA) from Gram-positive bacteria (S. aureus, S. epidermidis), activate the TLR-4 and TLR-2 signalling pathways in keratinocytes. This activation leads to uncontrolled inflammation and cellular damage. Inflammatory skin disorders, such as atopic dermatitis and chronic wounds, are often exacerbated by these pathways.
objectivesThis study elucidates the protective mechanisms of kaempferol, a natural flavonoid, against LPS + LTA-induced cytotoxicity and inflammation in HaCaT keratinocytes and a murine model of systemic inflammation.
methodsIn vitro, HaCaT cells were pretreated with kaempferol before exposure to LPS/LTA, followed by assessments of viability (MTT), apoptosis (Annexin V/PI), cytokine levels (ELISA), mRNA expression (qPCR), and protein expression (western blot). For in vivo studies, BALB/c mice were divided into five groups: (1) saline control (i.p.); (2) LPS/LTA (i.p.); and (3-5) kaempferol pretreatment (25, 50, 75 mg/kg, oral) before LPS/LTA challenge. Inflammatory markers were evaluated via ELISA, histopathology (H&E and Picro-Sirius red staining), and western blot.
resultsKaempferol significantly reduced apoptosis and suppressed the secretion of pro-inflammatory cytokines, including IL-6, IL-1β, and TNF-α. Mechanistically, it inhibited the phosphorylation of NF-κB p65 and MAPK (p38/JNK) by downregulating TLR-2 and TLR-4 expression in both HaCaT keratinocytes and an LPS + LTA-induced systemic model. These actions resulted in reduced liver inflammatory foci and collagen deposition. Furthermore, kaempferol interfered with MyD88-dependent signalling, lowered ROS overproduction, and inhibited IRF3 activity.
conclusionKaempferol differentially modulates TLR-2/TLR-4 crosstalk, thereby mitigating bacterial toxin-induced inflammation in both HaCaT keratinocytes and systemic model. This modulation was evidenced by a reduction in inflammatory foci and TLR activation in liver tissues, suggesting a novel therapeutic approach for skin inflammation. Furthermore, its dual TLR antagonism and cytoprotective effects could potentially surpass those of synthetic inhibitors, thereby enhancing its translational potential for treating TLR-mediated dermatological conditions.
Indexed as
Identifiers
40911079What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.